fah hospital policy blog

Perspectives on health policy affecting America’s hospitals and the patients we serve.

Category Archives: pharmaceuticals

ICYMI: FAH/AHA Drug Pricing Study Continues to Make Headlines

January 11, 2017 | FAH Policy Blog Team

Category: FAH News, Media, Pharmaceuticals

The website Healthcare Dive recently refocused the spotlight on the FAH/AHA hospital drug pricing study by publishing a feature article entitled, “How hospitals can fight the cost of budget-busting drugs.”

Read More »

FAH, AHA Sponsored Drug Pricing Study Gains National Media Attention

October 13, 2016 | FAH Policy Blog Team

Category: FAH News, Financing, Pharmaceuticals

A new analysis of drug pricing data released on October 11 got the attention of influential policymakers and garnered headlines nationwide after finding that hospital drug costs increased drastically over a two year period.

Read More »

Local Hospital Supports Bipartisan Fix to Skyrocketing Prescription Prices

July 25, 2016 | FAH Policy Blog Team

Category: Health Care Delivery, Pharmaceuticals

The CEO of a hospital in rural Iowa expressed his support for common sense solutions to help solve the prescription drug pricing crisis in an op-ed published in Sunday’s Des Moines Register.

Phil Noel, CEO of Ottumwa Regional Health Center in Ottumwa Iowa, laid out how rising medication costs are effecting his hospital and the patients it serves.

“This problem is acute. The high cost of cancer drugs made it impossible for our organization to continue to offer medical oncology. Additionally, the boutique infusion drugs have increased in usage and cost with a high financial burden to patients and hospitals that administer them,” he wrote.

Ottumwa Regional Health Centers is owned by Federation of American Hospitals member company RCCH HealthCare Partners.

Read More »

FAH Concerned about FDA’s Draft Guidance about Drug Compounding

July 20, 2016 | FAH Policy Blog Team

Category: FAH News, Legislation, Pharmaceuticals

The Federation of American Hospitals commented to the Food and Drug Administration Monday on the agency’s latest detailed draft guidance document implementing provisions of the revised Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act). The FAH letter expresses serious concerns about the current draft guidance and its impact on the provision of appropriate patient care.

Read More »